Baseline Characteristics From ENGAGE and EMERGE: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease (P4.1-001)

We describe baseline characteristics from ENGAGE (NCT02477800) and EMERGE (NCT02484547), ongoing Phase 3 studies of similar designs evaluating aducanumab in patients with early AD (MCI due to AD or mild AD dementia).